Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SF3B3 | Q15393 | 10/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3614540 | 0.92 | SF3B3 (0.58) | SF3B3 | |
| SCHEMBL12939266 | 0.92 | SF3B3 (0.52) | SF3B3 | |
| SCHEMBL3628613 | 0.92 | SF3B3 (0.58) | SF3B3 | |
| SCHEMBL3624840 | 0.90 | SF3B3 (0.62) | SF3B3 | |
| SCHEMBL3624837 | 0.90 | SF3B3 (0.61) | SF3B3 | |
| SCHEMBL3552320 | 0.90 | SF3B3 (0.56) | SF3B3 | |
| SCHEMBL3614574 | 0.90 | SF3B3 (0.48) | SF3B3 | |
| SCHEMBL3628611 | 0.89 | SF3B3 (0.66) | SF3B3 | |
| SCHEMBL3617825 | 0.88 | SF3B3 (0.65) | SF3B3 | |
| SCHEMBL12724009 | 0.87 | SF3B3 (0.62) | SF3B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655442-B2 | Efficiently producing a macrolide compound, in which a cyclodextrin is made to be present in a culture broth of actinomycetes; antitumor agents | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-02 | — | — | US | claimed |
| US-20070155696-A1 | Method for stabilizing macrolide compounds | MERCIAN CORPORATION (JP) | 2007-07-05 | — | — | US | claimed |
| EP-1710244-A1 | METHOD OF STABILIZING MACROLIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2006-10-11 | — | — | EP | claimed |
| US-7026352-B1 | Physiologically active substances | MERCIAN CORPORATION (JP) | 2006-04-11 | — | — | US | claimed |
| US-7932083-B2 | Ferrodoxins; hydroxylases; self-replicating plasmid | MERCIAN CORPORATION (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7932083-B2 | Ferrodoxins; hydroxylases; self-replicating plasmid | MERCIAN CORPORATION (JP) | 2011-04-26 | — | — | US | disclosed |
| EP-2277880-A1 | Macrolides with VEGF transcription suppression activity | Eisai R&D Management Co., Ltd. (JP) | 2011-01-26 | — | — | EP | disclosed |
| US-7667052-B2 | Bioactive substance | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-7667052-B2 | Bioactive substance | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-7667052-B2 | Bioactive substance | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-7655442-B2 | Efficiently producing a macrolide compound, in which a cyclodextrin is made to be present in a culture broth of actinomycetes; antitumor agents | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-02 | — | — | US | disclosed |
| US-20080070286-A1 | Dna Participating in Hydroxylation of Macrolide Compound | SANLI HOLDINGS CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| US-20080070286-A1 | Dna Participating in Hydroxylation of Macrolide Compound | SANLI HOLDINGS CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| US-20070155696-A1 | Method for stabilizing macrolide compounds | MERCIAN CORPORATION (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1710244-A1 | METHOD OF STABILIZING MACROLIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-20060079572-A1 | Novel bioactive substance | MICROBIOPHARM JAPAN CO., LTD. (JP) | 2006-04-13 | — | — | US | disclosed |
| US-7026352-B1 | Physiologically active substances | MERCIAN CORPORATION (JP) | 2006-04-11 | — | — | US | disclosed |
| EP-1380579-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | MERCIAN CORPORATION (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079572-A1 | Novel bioactive substance | CASP7, MMP7, BMP4 | SF3B3 2363/4885 |
| US-20070155696-A1 | Method for stabilizing macrolide compounds | MRPL21, ERG28, RPN1 | SF3B3 2845/4885 |
| US-20080070286-A1 | Dna Participating in Hydroxylation of Macrolide Compound | CYP51A1, DNMT3A, HSD17B10 | SF3B3 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.